Effect of a New Formulation of Torasemide (Prolonged Release)on Myocardial Fibrosis in Patients With Heart Failure.

PHASE4CompletedINTERVENTIONAL
Enrollment

142

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions
Congestive Heart Failure
Interventions
DRUG

Torasemide Prolonged Release

Torasemide Prolonged release 10mg/day up to 40mg/day, treatment duration:8 months

DRUG

Furosemide

Furosemide 40mg/day up to 160mg/day, Treatment duration:8 months

Trial Locations (23)

Unknown

Clinc Hospital, Barcelona

Germans Trias i Pujol Hospital, Barcelona

H. del Mar, Barcelona

Valle Hebrón Hospital, Barcelona

Canet de Mar, Primary Care Centre, Canet de Mar

Centelles - Primar Care Centre, Centellas

El Maresme - Primary Care Centre, Mataró

Remei, Primary care centre, Vic

Reina Sofia Hospital, Córdoba

Josep Trueta Hospital, Girona

San Jorge Hospital, Huesca

Complejo Hospitalario Juan Canalejo, A Coruña

Begonte - Primary Care Centre, Begonte

Gregorio Marañón Hospital, Madrid

Clinico Universitario Virgen de la Victoria, Málaga

Virgen de la Arrixaca, Murcia

Central Hospital, Oviedo

Clinico Universitario Hospital, Salamanca

Donostia Hospital, Donostia / San Sebastian

Clinico Universitario de Santiago, Santiago de Compostela

Alcover - primary care centre, Alcover

General Hospital, Valencia

Clinico Universitario, Zaragoza

All Listed Sponsors
lead

Ferrer Internacional S.A.

INDUSTRY

NCT00409942 - Effect of a New Formulation of Torasemide (Prolonged Release)on Myocardial Fibrosis in Patients With Heart Failure. | Biotech Hunter | Biotech Hunter